Cargando…

Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers

BACKGROUND: We have recently published SL-BioDP, a web resource for querying, exploration and visualization of potential synthetic lethal targets and possible synergistic drug combinations for 18 cancer types. METHODS: From our predictive synthetic lethality model used in SL-BioDP, we inferred TP53...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Shaoli, Deng, Xiang, Camphausen, Kevin, Shankavaram, Uma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644110/ https://www.ncbi.nlm.nih.gov/pubmed/33163985

Ejemplares similares

Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response
por: Das, Shaoli, et al.
Publicado: (2019)

SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment
por: Deng, Xiang, et al.
Publicado: (2019)

Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies
por: Das, Shaoli, et al.
Publicado: (2020)

In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data
por: Das, Shaoli, et al.
Publicado: (2020)

Glioma-BioDP: database for visualization of molecular profiles to improve prognosis of brain cancer
por: Deng, Xiang, et al.
Publicado: (2023)

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

Synthetic lethality between TP53 and ENDOD1
por: Tang, Zizhi, et al.
Publicado: (2022)

Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation
por: Krauze, Andra V., et al.
Publicado: (2023)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
por: Zhang, Baoyuan, et al.
Publicado: (2020)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

An inactivating mutation in the histone deacetylase SIRT6 causes human perinatal lethality
por: Ferrer, Christina M., et al.
Publicado: (2018)

Novel Murine Biomarkers of Radiation Exposure Using An Aptamer-Based Proteomic Technology
por: Sproull, Mary, et al.
Publicado: (2021)

CSNK1E/CTNNB1 Are Synthetic Lethal To TP53 in Colorectal Cancer and Are Markers for Prognosis
por: Tiong, Khong-Loon, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
por: Kim, Stephanie S., et al.
Publicado: (2020)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation
por: Seo, Sung-Keum, et al.
Publicado: (2014)

Correlation of Plasma FL Expression with Bone Marrow Irradiation Dose
por: Sproull, Mary, et al.
Publicado: (2013)

Visualizing Molecular Profiles of Glioblastoma with GBM-BioDP
por: Celiku, Orieta, et al.
Publicado: (2014)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
por: IMAI, HIROO, et al.
Publicado: (2014)

Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
por: Mrakovcic, Maria, et al.
Publicado: (2017)

Molecular profiling of MPS1 gene silencing in U251 glioma cell line
por: Shankavaram, Uma, et al.
Publicado: (2015)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors
por: Li, Shang, et al.
Publicado: (2011)

Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
por: Pal, Dilipkumar, et al.
Publicado: (2023)

Modulation of miR-21 signaling by MPS1 in human glioblastoma
por: Maachani, Uday B., et al.
Publicado: (2015)

Radiation-induced alternative transcripts as detected in total and polysome-bound mRNA
por: Wahba, Amy, et al.
Publicado: (2017)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
por: Maneix, Laure, et al.
Publicado: (2022)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma
por: Shankavaram, Uma T, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n5ek8udnvloicsi0lrnc6rhhjh